The NSCLS adenocarcinoma is reported associated with the aberrations like the epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusion or rearrangement [3, 5], and several drugs such as gefitinib, erlotinib, and afatinib were developed for the targeting the aberrant gene products, but only few patients are ideal for the targeted treatments [6]. Here, ALK is linked to adenocarcinoma.